TDMS Study 05004-04 Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
FURAN
NTP Experiment-Test: 05004-04 Report: PEIRPT05
Study Type: CHRONIC Date: 09/03/94
Route: GAVAGE Time: 02:49:52
Facility: Southern Research Institute
Chemical CAS #: 110-00-9
Lock Date: None
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05004-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC FURAN Date: 09/03/94
Route: GAVAGE Time: 02:49:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 8. MG/KG 15.
CONTROL MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50
Early Deaths
Moribund 16 16 35
Natural Death 1 1
Dead 4 8 11
Dosing Accident 1
Survivors
Terminal Sacrifice 28 25 2
Dead 1
Other 1
Animals Examined Microscopically 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (50) (50) (50)
Squamous Cell Papilloma 1 (2%)
Gallbladder (49) (49) (43)
Intestine Small, Duodenum (49) (47) (45)
Polyp Adenomatous 1 (2%)
Intestine Small, Ileum (48) (47) (44)
Liver (50) (50) (50)
Carcinoma 1 (2%)
Hemangiosarcoma 1 (2%)
Hepatocellular Carcinoma 2 (4%) 6 (12%) 22 (44%)
Hepatocellular Carcinoma, Multiple, Two 4 (8%)
Hepatocellular Carcinoma, Multiple, Three 1 (2%)
Hepatocellular Adenoma 5 (10%) 17 (34%) 8 (16%)
Hepatocellular Adenoma, Multiple, Two 8 (16%) 4 (8%)
Hepatocellular Adenoma, Multiple, Three 4 (8%) 10 (20%)
Hepatocellular Adenoma, Multiple, Four 2 (4%) 4 (8%)
Hepatocellular Adenoma, Multiple, Five 8 (16%)
Hepatocellular Adenoma, Multiple, Greater
Than Five 14 (28%)
Sarcoma, Metastatic 1 (2%)
Sarcoma Stromal, Metastatic, Uterus 1 (2%)
Mesentery (24) (27) (4)
Carcinoma, Metastatic, Liver 1 (4%)
Hemangiosarcoma 1 (4%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (25%)
Sarcoma, Metastatic 1 (4%) 1 (4%)
Sarcoma Stromal, Metastatic, Uterus 1 (4%)
Pancreas (50) (49) (50)
Carcinoma, Metastatic, Liver 1 (2%)
Page 2
NTP Experiment-Test: 05004-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC FURAN Date: 09/03/94
Route: GAVAGE Time: 02:49:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 8. MG/KG 15.
CONTROL MG/KG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Sarcoma, Metastatic 1 (2%) 1 (2%)
Sarcoma Stromal, Metastatic, Uterus 1 (2%)
Salivary Glands (50) (50) (50)
Adventitia, Hemangioma 1 (2%)
Stomach, Forestomach (50) (49) (49)
Mucosa, Squamous Cell Papilloma 2 (4%) 6 (12%) 3 (6%)
Stomach, Glandular (49) (49) (50)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (50) (50) (50)
Extra Adrenal Tissue, Carcinoma, Metastatic,
Liver 1 (2%)
Subcapsular, Adenoma 1 (2%)
Adrenal Gland, Medulla (50) (50) (50)
Pheochromocytoma Benign 2 (4%) 1 (2%) 3 (6%)
Pheochromocytoma Benign, Multiple 3 (6%)
Islets, Pancreatic (50) (50) (50)
Carcinoma 1 (2%)
Pituitary Gland (49) (47) (46)
Adenoma 1 (2%)
Pars Distalis, Adenoma 25 (51%) 18 (38%) 9 (20%)
Pars Distalis, Carcinoma 1 (2%)
Pars Intermedia, Adenoma 1 (2%)
Thyroid Gland (50) (50) (50)
Follicular Cell, Adenoma 2 (4%) 3 (6%) 1 (2%)
Follicular Cell, Adenoma, Multiple, Two 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (1) (1)
Abdominal, Sarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (49) (49) (50)
Cystadenoma, Papillary 1 (2%)
Granulosa Cell Tumor Benign 1 (2%)
Granulosa-Theca Tumor Benign 1 (2%)
Page 3
NTP Experiment-Test: 05004-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC FURAN Date: 09/03/94
Route: GAVAGE Time: 02:49:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 8. MG/KG 15.
CONTROL MG/KG
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - cont
Periovarian Tissue, Carcinoma, Metastatic,
Liver 1 (2%)
Oviduct (4) (4) (1)
Carcinoma, Metastatic, Liver 1 (25%)
Uterus (50) (50) (50)
Hemangiosarcoma 1 (2%)
Sarcoma Stromal 2 (4%)
Endometrium, Polyp Stromal 1 (2%) 4 (8%)
Endometrium, Polyp Stromal, Multiple 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Blood (1) (1)
Bone Marrow (50) (50) (50)
Hemangiosarcoma 1 (2%)
Lymph Node (50) (50) (50)
Lymph Node, Bronchial (21) (29) (21)
Lymph Node, Mandibular (47) (46) (48)
Lymph Node, Mediastinal (41) (45) (43)
Lymph Node, Mesenteric (49) (49) (49)
Spleen (50) (50) (50)
Hemangiosarcoma 1 (2%) 2 (4%)
Thymus (46) (46) (45)
Epithelial Cell, Thymoma Benign 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (49) (50) (48)
Adenocarcinoma 2 (4%) 1 (2%) 3 (6%)
Carcinoma 1 (2%)
Skin (50) (50) (50)
Squamous Cell Carcinoma 1 (2%)
Head, Sebaceous Gland, Adenoma 1 (2%)
Sebaceous Gland, Adenoma 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
Subcutaneous Tissue, Sarcoma 1 (2%)
Subcutaneous Tissue, Sarcoma, Metastatic 1 (2%)
Tail, Squamous Cell Papilloma 1 (2%)
Tail, Subcutaneous Tissue, Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 05004-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC FURAN Date: 09/03/94
Route: GAVAGE Time: 02:49:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 8. MG/KG 15.
CONTROL MG/KG
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (3) (2)
Abdominal, Sarcoma 1 (50%)
Diaphragm, Sarcoma, Metastatic 1 (50%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50)
Meningioma Benign 1 (2%)
Peripheral Nerve (1)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50)
Adenocarcinoma, Multiple, Metastatic,
Greater Than Five, Mammary Gland 1 (2%)
Alveolar/Bronchiolar Adenoma 3 (6%) 4 (8%) 3 (6%)
Alveolar/Bronchiolar Carcinoma 2 (4%) 2 (4%) 1 (2%)
Hemangiosarcoma 1 (2%)
Hepatocellular Carcinoma, Multiple,
Metastatic, Three, Liver 1 (2%)
Hepatocellular Carcinoma, Multiple,
Metastatic, Four, Liver 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) 1 (2%)
Sarcoma, Metastatic 1 (2%)
Parenchyma, Mediastinum, Carcinoma,
Metastatic, Liver 1 (2%)
Nose (50) (50) (50)
Trachea (50) (50) (50)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (4) (6) (4)
Adenoma 2 (50%) 4 (67%) 2 (50%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (49)
Urinary Bladder (50) (50) (50)
Page 5
NTP Experiment-Test: 05004-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC FURAN Date: 09/03/94
Route: GAVAGE Time: 02:49:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 8. MG/KG 15.
CONTROL MG/KG
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50)
Lymphoma Malignant Lymphocytic 3 (6%) 3 (6%)
Lymphoma Malignant Mixed 17 (34%) 11 (22%) 7 (14%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 6
NTP Experiment-Test: 05004-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC FURAN Date: 09/03/94
Route: GAVAGE Time: 02:49:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 8. MG/KG 15.
CONTROL MG/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 43 43 50
Total Primary Neoplasms 83 101 124
Total Animals with Benign Neoplasms 34 38 48
Total Benign Neoplasms 48 71 82
Total Animals with Malignant Neoplasms 30 24 32
Total Malignant Neoplasms 35 30 42
Total Animals with Metastatic Neoplasms 4 2 3
Total Metastatic Neoplasm 7 12 4
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 7
NTP Experiment-Test: 05004-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC FURAN Date: 09/03/94
Route: GAVAGE Time: 02:49:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 8. MG/KG 15.
CONTROL MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50
Early Deaths
Moribund 16 24 24
Dead 1 5 8
Natural Death 1 1
Dosing Accident 2
Accident 1
Survivors
Terminal Sacrifice 33 17 16
Other 1
Animals Examined Microscopically 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (50) (48) (44)
Adenocarcinoma, Metastatic, Liver 1 (2%)
Intestine Small, Duodenum (49) (49) (48)
Adenocarcinoma, Metastatic, Uncertain
Primary Site 1 (2%)
Serosa, Sarcoma, Metastatic, Uncertain
Primary Site 1 (2%)
Intestine Small, Jejunum (50) (49) (48)
Adenocarcinoma 1 (2%)
Liver (50) (50) (50)
Adenocarcinoma, Metastatic, Uncertain
Primary Site 1 (2%)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Carcinoma, Multiple, Metastatic, Harderian
Gland 1 (2%)
Hemangiosarcoma 2 (4%) 1 (2%) 2 (4%)
Hemangiosarcoma, Multiple, Two 2 (4%)
Hemangiosarcoma, Multiple, Three 1 (2%)
Hepatoblastoma 1 (2%)
Hepatocellular Carcinoma 5 (10%) 26 (52%) 27 (54%)
Hepatocellular Carcinoma, Multiple 2 (4%)
Hepatocellular Carcinoma, Multiple, Two 1 (2%) 3 (6%) 5 (10%)
Hepatocellular Carcinoma, Multiple, Three 1 (2%) 1 (2%)
Hepatocellular Carcinoma, Multiple, Four 1 (2%)
Hepatocellular Carcinoma, Two 1 (2%)
Hepatocellular Adenoma 18 (36%) 16 (32%) 12 (24%)
Hepatocellular Adenoma, Multiple, Two 1 (2%) 8 (16%) 11 (22%)
Hepatocellular Adenoma, Multiple, Three 6 (12%) 8 (16%)
Page 8
NTP Experiment-Test: 05004-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC FURAN Date: 09/03/94
Route: GAVAGE Time: 02:49:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 8. MG/KG 15.
CONTROL MG/KG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Hepatocellular Adenoma, Multiple, Four 1 (2%) 4 (8%)
Hepatocellular Adenoma, Multiple, Five 1 (2%) 2 (4%)
Hepatocellular Adenoma, Multiple, Greater
Than Five 1 (2%) 3 (6%)
Hepatocellular Adenoma, Two 1 (2%) 2 (4%)
Hepatocholangiocarcinoma 2 (4%)
Ito Cell Tumor Benign 1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (2%)
Biliary Tract, Adenocarcinoma 2 (4%) 2 (4%)
Mesentery (6) (10) (3)
Adenocarcinoma, Multiple, Metastatic,
Uncertain Primary Site 1 (10%)
Adenocarcinoma, Multiple, Metastatic,
Greater Than Five, Liver 1 (33%)
Adenocarcinoma, Metastatic, Liver 2 (20%)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (10%)
Carcinoma, Metastatic, Harderian Gland 1 (10%)
Hemangiosarcoma 1 (17%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (10%)
Hepatocholangiocarcinoma, Multiple,
Metastatic, Liver 1 (10%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (10%)
Pancreas (50) (50) (50)
Adenocarcinoma, Metastatic, Liver 1 (2%) 1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (2%)
Salivary Glands (50) (50) (48)
Stomach, Forestomach (49) (50) (50)
Mucosa, Squamous Cell Papilloma 1 (2%) 3 (6%)
Stomach, Glandular (49) (50) (50)
Carcinoid Tumor Malignant 1 (2%) 1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (2%)
Tooth (43) (36) (32)
Peridontal Tissue, Carcinoma, Metastatic,
Harderian Gland 1 (3%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Carcinoma, Multiple, Metastatic, Harderian
Gland 1 (2%)
Hemangiosarcoma 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 3 (6%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Page 9
NTP Experiment-Test: 05004-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC FURAN Date: 09/03/94
Route: GAVAGE Time: 02:49:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 8. MG/KG 15.
CONTROL MG/KG
____________________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (50) (50) (50)
Adenoma 2 (4%) 1 (2%)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Extra Adrenal Tissue, Sarcoma, Metastatic,
Uncertain Primary Site 1 (2%)
Subcapsular, Adenoma 3 (6%) 2 (4%)
Subcapsular, Adenoma, Multiple 1 (2%)
Adrenal Gland, Medulla (49) (50) (50)
Pheochromocytoma Benign 5 (10%) 7 (14%)
Pheochromocytoma Benign, Multiple 1 (2%) 1 (2%) 3 (6%)
Pituitary Gland (50) (44) (48)
Pars Distalis, Adenoma 1 (2%)
Pars Intermedia, Adenoma 1 (2%)
Thyroid Gland (50) (50) (50)
Follicular Cell, Adenoma 1 (2%)
Follicular Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ductus Deferens (1) (2)
Epididymis (50) (50) (50)
Preputial Gland (6) (6) (5)
Adenoma 1 (17%)
Prostate (49) (50) (50)
Seminal Vesicle (50) (50) (50)
Adenocarcinoma, Metastatic, Liver 1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (2%)
Testes (50) (50) (50)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50)
Hemangiosarcoma 2 (4%) 1 (2%)
Lymph Node (50) (50) (49)
Lymph Node, Bronchial (14) (27) (26)
Lymph Node, Mandibular (49) (48) (43)
Lymph Node, Mediastinal (38) (45) (41)
Page 10
NTP Experiment-Test: 05004-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC FURAN Date: 09/03/94
Route: GAVAGE Time: 02:49:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 8. MG/KG 15.
CONTROL MG/KG
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Adenocarcinoma, Metastatic, Liver 1 (2%) 1 (2%)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (2%)
Lymph Node, Mesenteric (50) (50) (48)
Adenocarcinoma, Metastatic, Liver 1 (2%)
Spleen (50) (50) (49)
Adenocarcinoma, Metastatic, Liver 1 (2%)
Hemangiosarcoma 3 (6%) 2 (4%)
Thymus (42) (44) (42)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (50) (50)
Fibrosarcoma 1 (2%)
Squamous Cell Papilloma 1 (2%)
Subcutaneous Tissue, Fibroma 3 (6%)
Subcutaneous Tissue, Fibrosarcoma 3 (6%) 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
Subcutaneous Tissue, Neurofibroma 1 (2%)
Subcutaneous Tissue, Sarcoma 2 (4%) 2 (4%)
Subcutaneous Tissue, Sarcoma, Multiple 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50)
Cranium, Carcinoma, Metastatic, Harderian
Gland 1 (2%)
Cranium, Hemangiosarcoma 1 (2%)
Skeletal Muscle (2) (3) (1)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (33%)
Back, Hemangiosarcoma 1 (50%)
Diaphragm, Intercostal, Alveolar/Bronchiolar
Carcinoma, Multiple, Metastatic, Lung 1 (33%)
Head, Carcinoma, Metastatic, Harderian Gland 1 (33%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (49)
Adenocarcinoma, Metastatic, Liver 1 (2%)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Meninges, Hemangiosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
Page 11
NTP Experiment-Test: 05004-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC FURAN Date: 09/03/94
Route: GAVAGE Time: 02:49:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 8. MG/KG 15.
CONTROL MG/KG
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50)
Adenocarcinoma, Multiple, Metastatic,
Uncertain Primary Site 1 (2%)
Adenocarcinoma, Multiple, Metastatic,
Greater Than Five, Liver 1 (2%)
Adenocarcinoma, Metastatic, Liver 1 (2%)
Alveolar/Bronchiolar Adenoma 7 (14%) 6 (12%) 12 (24%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%)
Alveolar/Bronchiolar Adenoma, Multiple, Two 1 (2%) 1 (2%) 4 (8%)
Alveolar/Bronchiolar Carcinoma 3 (6%) 2 (4%)
Carcinoma 1 (2%)
Hepatocellular Carcinoma, Multifocal,
Metastatic, Greater Than Five, Liver 1 (2%)
Hepatocellular Carcinoma, Multiple,
Metastatic, Liver 1 (2%) 1 (2%)
Hepatocellular Carcinoma, Multiple,
Metastatic, Three, Liver 1 (2%)
Hepatocellular Carcinoma, Metastatic 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 2 (4%) 4 (8%) 2 (4%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Mediastinum, Adenocarcinoma, Metastatic,
Liver 1 (2%)
Mediastinum, Sarcoma, Metastatic, Uncertain
Primary Site 1 (2%)
Parenchyma, Mediastinum,
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%)
Parenchyma, Mediastinum, Carcinoma, Multiple,
Metastatic, Harderian Gland 1 (2%)
Nose (50) (50) (50)
Mucosa, Carcinoma, Metastatic, Harderian
Gland 1 (2%)
Mucosa, Hemangiosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Ear (1)
Glioma Malignant, Metastatic 1 (100%)
Eye (1)
Carcinoma, Metastatic, Harderian Gland 1 (100%)
Harderian Gland (3) (5)
Adenoma 3 (100%) 4 (80%)
Carcinoma 1 (20%)
____________________________________________________________________________________________________________________________________
Page 12
NTP Experiment-Test: 05004-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC FURAN Date: 09/03/94
Route: GAVAGE Time: 02:49:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 8. MG/KG 15.
CONTROL MG/KG
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50)
Adenocarcinoma, Metastatic, Liver 1 (2%)
Alveolar/Bronchiolar Carcinoma, Multiple,
Metastatic, Lung 1 (2%)
Hepatocellular Carcinoma, Multiple,
Metastatic, Liver 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Adventitia, Adenocarcinoma, Metastatic, Liver 1 (2%)
Capsule, Sarcoma, Metastatic, Uncertain
Primary Site 1 (2%)
Urinary Bladder (50) (49) (50)
Transitional Epithelium, Papilloma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50)
Lymphoma Malignant Histiocytic 1 (2%) 1 (2%)
Lymphoma Malignant Mixed 5 (10%) 11 (22%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 13
NTP Experiment-Test: 05004-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC FURAN Date: 09/03/94
Route: GAVAGE Time: 02:49:52
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 8. MG/KG 15.
CONTROL MG/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 43 45 50
Total Primary Neoplasms 75 122 121
Total Animals with Benign Neoplasms 32 38 46
Total Benign Neoplasms 45 57 73
Total Animals with Malignant Neoplasms 19 41 39
Total Malignant Neoplasms 30 65 48
Total Animals with Metastatic Neoplasms 3 10 3
Total Metastatic Neoplasm 3 62 8
Total Animals with Malignant Neoplasms 3
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 14
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------
--multipart-boundary
Content-type: text/plain
Range: bytes 85204-85204/85204
--multipart-boundary--